Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

doi:10.1200/JCO-25-00225

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Sept 2025

Konstantinopoulos Panagiotis A, Kim Jae Weon, Freyer Gilles, Lee Jung Yun, Gaba Lydia, Grisham Rachel N, Colombo Nicoletta, Wu Xiaohua, Sehouli Jalid, Cruz Felipe, Cibula David, Monk Bradley J, Nyvang Gitte-Bettina, Friedlander Michael, Lorusso Domenica, Van Nieuwenhuysen Els, Malik Rozita, Glasspool Rosalind, Marth Christian, Leary Alexandra, Cortés-Salgado Alfonso, Zamagni Claudio, Marmé Frederik, Sufliarsky Jozef, Hinson Patsy, Zuradelli Monica, Wang Craig, Su Fei, Paule Ines, Miller Michelle, Matulonis Ursula A, González-Martín Antonio

Abstract excerpt

PURPOSE: Patients with platinum-resistant/platinum-refractory high-grade serous ovarian cancer (HGSOC) without a BRCA mutation have poor prognosis and limited treatment options. We report efficacy and biomarker data from EPIK-O, which investigated alpelisib + olaparib versus single-agent chemotherapy in these patients. PATIENTS AND METHODS: EPIK-O was an open-label, phase III trial that randomly assigned patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Cystadenocarcinoma, Serous

Share to Ovarian Neoplasms

Share to Phthalazines

Share to Piperazines

Share to Progression-Free Survival

Source

Open in PubMed

Identifiers

PMID: 40700681
DOI: 10.1200/JCO-25-00225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.PMID 40700681Read ↗

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)Semantic proximity Read ↗

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.Semantic proximity Read ↗

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.Semantic proximity Read ↗

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)Semantic proximity Read ↗

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancerSemantic proximity Read ↗

Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trialSemantic proximity Read ↗

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)Semantic proximity Read ↗

Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.Semantic proximity Read ↗

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.Semantic proximity Read ↗

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)Semantic proximity Read ↗

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.Semantic proximity Read ↗

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer in 2018–2023 and the Impact of Molecular Diagnostics on the Chemotherapy in Clinical PracticeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.